Biogen’s Aduhelm sales fall dramatically below Wall Street’s expectations
Biogen made just $300,000 from the Alzheimer’s disease treatment Aduhelm in the first full quarter since its approval.
Related Articles
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Pharmalittle: We’re reading about Medicare plans to negotiate obesity-drug prices, a Novartis 340B lawsuit, and more
Medicare announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy
Pharmalittle: We’re reading about lower-priced Zepbound vials, monkey shipments from Cambodia, and more
Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound
International monitor recommends end to some monkey shipments from Cambodia
Officials who oversee an international treaty governing endangered species recommended suspending shipments of long-tailed macaques — which are regularly used in medical research — from…
Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb their practices
NIH issues a policy to widen access to medical products that emerge from government-funded research
NIH policy asks companies seeking licenses to sell medical products invented with government research to submit plans for ensuring greater access to patients.
FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
Pharmalittle: We’re reading about pharma asking Trump to pause Medicare talks, a Truveta database launch, and more
Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations
Pharmalittle: We’re reading about J&J and GSK deals, a departing FDA official, and more
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large drugmakers
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.